GSK is to invest £1 billion over the course of 10 years into research on infectious diseases that largely affect low-income countries. In particular, the pharmaceutical company will aim to develop new vaccines and medicines that prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR) – all […]